venerdì, 27 novembre 2020
27 Aprile 2018

Lead Author Explains ASCO’s Statement on Biosimilars in Oncology

April 26, 2018 – ASCO recently released a statement outlining the organization’s commitment to education and guidance regarding the use of biosimilars in the treatment of patients with cancer, which was published in the Journal of Clinical Oncology. The statement focused on the value of biosimilars in oncology, naming and labeling, safety and efficacy, interchangeability, and prescriber and patient education. “ASCO’s goal is primarily to educate and inform … (leggi tutto)